Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lailotinib versus chemotherapy in previously treated EGFR-overexpressing advanced esophageal squamous cell carcinoma
CTR20201009Phase 3Active
- Sponsor
- HEC Pharm
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lailotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by HEC Pharm. Started Jan 2021; status: active.
02
Drugs
lailotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20201009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201009.